Biochemical Profile and Assessment of risk factors for Patients Diagnosed with Myocardial Infarction in Al-Ramadi City, Iraq

Abstract = 10 times | PDF = 46 times

Main Article Content

Marwan Mahmood Saleh


Myocardial infarction (MI) continues to be a major cause of mortality and also death at early ages all over the world. This study is undertaken to evaluate the effect of  MI on the levels of lipid profile, two  enzymatic markers, fasting blood sugar (FBS), urea, creatinine and total serum bilirubin (TSB), rather than to assess the risk factors which lead to MI and its relation to these variables. The sample of the study consisted of (50) patients admitted to the Cardiac Care Unit in Al-Ramadi General hospital. MI patients had significantly (P≤0.05)  higher levels of triglyceride (TG) (201.4 mg/dl) as compared with the controls (142.8 mg/dl), while high density lipoprotein (HDL) significantly (P≤0.05)  decreased in patients (42.24 mg/dl) compared with control group (58.7mg/dl). Total cholesterol (TC) (183.6 mg/dl) and low density lipoprotein (LDL) (109.3mg/dl) were not affected significantly (P≤0.05)  in MI group when compared with control group with the average of (172.2 mg/dl), (116 mg/dl) respectively. Aspartate aminotransferase (AST) increased significantly (P≤0.05) in patients (61.38 IU/L) compared to the control group (23.5 IU/L) , while there was no significant (P≤0.05) difference in alkaline phosphatase (ALP) between MI and control group. Levels of fasting blood sugar (FBS) in the serum of MI group (206 mg/dl) increased significantly (P≤0.05) comparing with the control group (122.1 mg/dl). This study showed increase in urea (55.6 mg/dl) and creatinine (1.26 mg/dl) levels in the MI group contrast with the control group which its mean was (29.8 mg/dl), ( 0.85 mg/dl) respectively. There was no difference in the level of TSB. Findings of this study, stating differences in levels of some biochemical parameters can use as a biomarker of myocardial infarction. There is an increase in the incidence of myocardial infarction and some differences in the level of parameters  in the presence of one or more major risk factors.


Download data is not yet available.

Article Details


[1] K. Thygesen, JS. Alpert, HD. White, AS. & AS. Jaffe, “Universal definition of myocardial infarction, ” Circulation, 116, pp. 2634-2653, 2007.
[2] K. Thygesen, JS. Alpert, AS. Jaffe, et al., “Third universal definition of myocardial infarction, ” J Am Coll Cardiol, 60, pp. 1581-98, 2012.
[3] L. Jeffrey, MD. Anderson, A. David & MD. Morrow, “Acute Myocardial Infarction, The new england journal of medicine,” 376(21), pp. 2053-2064, 2017.
[4] U.S. National library of medicine and the National Intstitutes of Health, Medical subject headings. 2013.
[5] DP. Zipes, P. Libby, RO. Bonow, & E. Braunwald, Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine, W.B. Saunders Company, Philadelphia, 7th edition, 2004.
[6] MJ. Davies, “The composition of coronary-artery plaques, ” N Engl J Med, 336(18), pp. 1312-4, 1997.
[7] SI. Rapaport & LV. Rao, “The tissue factor pathway: how it has become a "prima ballerina". Thromb Haemost, 74(1), pp. 7–17, 1995.
[8] American Heart Association, Understand your risk of heart attack, 2014.
[9] JS. Alpert, K. Thygesen, E. Antman, & JP. Bassand, “Myocardial Infarction Redefined, consensus of the Joint European society of cardiology American college of cardiology committee for the redefinition of myocardial infarction, Jam coll Cardiol, 36, pp. 959-969, 2000.
[10] RK. Archer, LB. Jeffcott, & H. Lehmann, “Comparative clinical haematology. Blackwell Scientific Publications, 1977.
[11] LG. Martinez, and L. Bucher, “Nursing management. Coronary artery disease and acute syndrome. Assessment and management of clinical problems,” 7th ed, 784-820, 2007.
[12] F. Chang, S. Baloch, MS. Pirzado, MM. Sahito, S. Baloch, et al., “Hematological and Biochemical Variations in Myocardial Infarction,” J Clin Case Rep, 5(11), pp. 648-649, 2015.
[13] S. Ahmad, M. Abdoljalal, & Z. Farhad, “Serum lipid profiles in acute myocardial infarction patients in Gorgan,” Biomedical Research, 23(1), pp. 119-124, 2012.
[14] S. Jayakrishnan, & B. Jayanthi, “Biochemical Markers and Myocardial Infarction,” Indian Journal of Research, 4(8), pp. 151-153, 2015.
[15] GF. Watts, P. Jackson, & S. Mandalia, “Nutrient intake and progression of coronary artery disease,” Am J Cardiol, 73, pp. 328-332, 1994.
[16] DS. Fredrickson, “The role of lipids in acute myocardial infarction,” Circulation, 39, Suppl. IV-99-IV-III, 1969.
[17] Zampogna A, Luria MH, Mancibens SJ, Luria MA. “Relationship between lipids and occlusive coronary disease,” Arch. Intern Med, 140, pp. 1067-1069, 1980.
[18] FC. Ballantyne, DA. Melville, JP. Mc Kenna, BA. Morrison, & D. Ballantyne, “Response of plasma lipoproteins and acute phase proteins to myocardial infarction,” Clin. Chim Acta, 99, pp. 85-92, 1979.
[19] MQ. Al-Ani, AM. Sameen, & AS. Farhan, “Study of Some Physiological and Biochemical Aspects in The Serum of Myocardial Infarction Patients, Journal of Kirkuk University – Scientific Studies, ” 6 (2), pp. 63-72, 2011.
[20] M. Crawfored, JP. DiMarco, & WJ. Paulus, Cardiology, 2nd ed., Mosby. Limited. Spain, 2004.
[21] G. Engstrom, P. Tyden, G. Berglund, O. Hansen, B. Hedblad, & L. Janzon, “ Incidence of myocardial infarction in women: A cohort study of risk factors and modifiers of effect,” Journal of Epidemiology and Community Health, 54, pp. 104-107, 2000.
[22] DS. Prasad, Z. Kabir, AK. Dash, & BC. Das, “Smoking and cardiovascular health: A review of the epidemiology, pathogenesis, prevention and control of tobacco,” Indian Journal of Medical Science, 63, pp. 520-533, 2009.
[23] M. Boaz, Z. Matas, A. Biro et al., Serum malondialdehyde and prevalent cardiovascular disease in hemodialysis,” Kidney Int, 56, pp. 1078–1083, 1999.
[24] D. Londero, & P. Lo Greco, “Automated high-performance liquid chromatographic separation with spectrofluorometric detection of a malondialdehyde-thiobarbituric acid adduct in plasma,” J Chromatography, 729, pp. 207–210, 1996.
[25] R. Avieles, A. Askari, B. Lindahl et al., “Troponin T levels in patients acute coronary syndromes with or without renal dysfunction,” N Engl J Med, 346, pp. 2047–2052, 2002.
[26] P. Holvoet, D. Collen, & F. Van de Werf, “Malodialdehyde-modified LDL as a marker of acute coronary syndromes, ” J Am Med Assoc, 281, pp. 1718–1721, 1999.
[27] J. Thambyrajah, M. Landray, F. McGlynn, H. Jones, D. Wheeler, J. Townend, “Abnormalities of endothelial function in patients with predialysis renal failure,” Heart, 83, pp. 205–209, 2000.
[28] J. Alpert, K. Thygeson, & E. Antman, “Myocardial infarction redefined – a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for redefinition of myocardial infarction,” J Am. Coll. Cardiol. 36, pp. 959-69, 2000.
[29] PH. Baal, M. Peter & K. Engelfriet, “Co-occurrence of diabetes, myocardial infarction,, Hendriek C Boshuizen1, Jan van de stroke, and cancer: quantifying age patterns in the Dutch population using health survey data,” Population Health Metrics, 9:51, 2011.
[30] J. Boras, Pavlic-Renar, N.Car, & Z. Metelko, “Diabetes and coronary heart disease, Diabetologia Croatica,” 31, pp. 199-208, 2002.
[31] SC. Smeltzer, & BG. Bare, Bruners & Suddarhs textbook of medical surgical marsing, 10th ed, Philadelphia, PA:Lippincott Williams &Wilkins, 2004.